SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用

doi:10.11904/j.issn.1002-3070.2022.06.005

Abstract

Abstract: Src homology region 2-containing protein tyrosine phosphatase 2(SHP2)is the only cytoplasmic protein tyrosine phosphatase that has been confirmed to promote cancer.There are highly expressed in a variety of malignant tumors.SHP2 can promote tumor development and affect tumor prognosis by mediating RAS/ERK,PI3K/Akt,JAK/STAT and other signal pathways downstream of receptor tyrosine kinase(RTK).At the same time,SHP2 is involved in the regulation of immune checkpoint signaling pathways such as PD-1 / PD-L1,CTLA-4,BLTA and TIGIT,and plays an important role in regulating various immune cells in the tumor microenvironment.Targeting SHP2 can treat malignant tumors not only by inhibiting RTK downstream signaling pathways,but also by improving the immune microenvironment.Therefore,SHP2 has the function of dual treatment tumor by immunity and targeting,and it shows extremely high potential and value as a target for anti-tumor therapy.

Key words: Protein tyrosine phosphatase 2 containing Src homology 2 domain, Tumor, Tumor immune microenvironment, Immunotherapy

CLC Number:

ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy[J]. Journal of Practical Oncology, 2022, 36(6): 513-519.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.06.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I6/513

References

1 Chen H,Libring S,Ruddraraju KV,et al.SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer[J].Oncogene,2022,39(49):7166-7180.
2 Nagamura Y,Miyazaki M,Nagano Y,et al.SHP2 as a potential therapeutic target in diffuse-type gastric carcinoma addicted to receptor tyrosine kinase signaling[J].Cancers(Basel),2021,13(17):4309.
3 Lazzara MJ,Lane K,Chan R,et al.Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations[J].Cancer Res,2010,70(9):3843-3850.
4 Cao M,Gao D,Zhang N,et al.Shp2 expression is upregulated in cervical cancer,and Shp2 contributes to cell growth and migration and reduces sensitivity to cisplatin in cervical cancer cells[J].Pathol Res Pract,2019,215(11):152621.
5 Frankel T,Lanfranca MP,Zou WP.The role of tumor microenvironment in cancer immunotherapy[J].Adv Exp Med Biol,2017,1036:51-64.
6 Liu QQ,Qu J,Zhao MX,et al.Targeting SHP2 as a promising strategy for cancer immunotherapy[J].Pharmacol Res,2020,152:104595.
7 Huang WQ,Lin Q,Zhuang X,et al.Structure,function,and pathogenesis of SHP2 in developmental disorders and tumorigenesis[J].Curr Cancer Drug Targets,2014,14(6):567-588.
8 Hof P,Pluskey S,Dhe-Paganon S,et al.Crystal structure of the tyrosine phosphatase SHP2[J].Cell,1998,92(4):441-450.
9 Jia Z,Ye Q,Dinaut AN,et al.Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics[J].J Med Chem,2001,44:4584-4594.
10 Miura K,Wakayama Y,Tanino M,et al.Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2 -regulated activation of extracellular signal-regulated kinase[J].Oncogene,2013,32(45):5292-5301.
11 胡中倩,张炽敏.蛋白酪氨酸磷酸酶SHP2基因及其与实体瘤关系[J].转化医学杂志,2013,2(2):113-116.
12 Liu FF,Yang XT,Geng MY,et al.Targeting ERK,an achilles′ heel of the MAPK pathway,in cancer therapy[J].Acta Pharm Sin B,2018,8(4):552-562.
13 Yuan XR,Bu H,Zhou JP,et al.Recent advances of SHP2 inhibitors in cancer therapy:current development and clinical application[J].J Med Chem,2020,63(20):11368-11396.
14 Liu C,Lu HY,W HY,et al.Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling[J].Clin Cancer Res,2021,27(1):342-354.
15 Ou SI,Koczywas M,Ulahannan S,et al.A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer:preliminary evaluation of a first-in-man phase 1 clinical trial[J].J Thorac Oncol,2020,15:15-16.
16 Fedele C,Li S,Teng KW,et al.SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling[J].J Exp Med,2021,218(1):e20201414.
17 Yuan Y,Fan YL,Gao ZC,et al.SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3β signaling pathway[J].Cancer Biol Med,2020,17(3):707-725.
18 Zhang WJ,Chan RJ,Chen HY,et al.Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia[J].J Biol Chem,2009,284(33):22353-22363.
19 Kim M,Morales LD,Jang I,et al.Protein tyrosine phosphatases as potential regulators of STAT3 signaling[J].Int J Mol Sci,2018,19(9):2708.
20 Song YH,Zhao M,Zhang HQ,et al.Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials[J].Pharmacol Ther,2022,230:107966.
21 Zehender A,Huang J,Gyorfi AH,et al.The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis[J].Nat Commun,2018,9(1):3259.
22 Thommen DS,Schumacher TN.T cell dysfunction in cancer[J].Cancer Cell,2018,33(4):547-562.
23 Liu W,Guo WJ,Shen LH,et al.T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice[J].Oncotarget,2017,8(5):7586-7897.
24 Hosseinzadeh R,Feizisani F,Shomali N,et al.PD-1/PD-L1 blockade:prospectives for immunotherapy in cancer and autoimmunity[J].IUBMB Life,2021,73(11):1293-1306.
25 Xia LL,Liu YY,Wang Y.PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer:current status and future directions[J].Oncologist,2019,24(Suppl 1):31-41.
26 Carlino MS,Larkin J,Long GV.Immune checkpoint inhibitors in melanoma[J].Lancet,2021,398(10304):1002-1014.
27 Okosuka T,Takamatsu M,Kobayashi-Imanishi W,et al.Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J].J Exp Med,2012,209(6):1201-1217.
28 Xu XZ,Hou BW,Fulzele A,et al.PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2[J].J Cell Biol,2020,219(6):e201905085.
29 Zhao JL,Roberts A,Wang ZL,et al.Emerging role of PD-1 in the central nervous system and brain diseases[J].Neurosci Bull,2021,37(8):1188-1202.
30 Zhao MX,Guo WJ,Wu YY,et al.SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade[J].Acta Pharm Sin B,2019,9(2):304-315.
31 Schneider H,Dias SR,Hu H,et al.A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling[J].Eur J Immunol,2001,31(7):2042-2050.
32 Xu XZ,Masubuchi T,Cai QX,et al.Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors[J].Elife,2021,10:e74276.
33 Liu XG,Hou M,Liu Y.TIGIT,a novel therapeutic target for tumor immunotherapy[J].Immunol Invest,2017,46(2):172-182.
34 Boutilier AJ,Elsawa SF.Macrophage polarization states in the tumor microenvironment[J].Int J Mol Sci,2021,22(13):6995.
35 Wang L,Iorio C,Yan K,et al.A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages[J].FASEB J,2018,32(2):875-887.
36 Li D,Xiong W,Wang YD,et al.SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors[J].Sci Immunol,2022,7(67):5501.
37 Gao J,Wu ZG,Zhao MX,et al.Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics[J].Acta Pharm Sin B,2022,12(1):149-166.
38 Song H,Song JX,Cheng M,et al.METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells[J].Nat Commun,2021,12(1):5522.
39 Friederichs K,Schmitz J,Weissenbach M,et al.Interleukin-6-induced proliferation of pre-B cells mediated by receptor complexes lacking the SHP2/SOCS3 recruitment sites revisited[J].Eur J Biochem,2001,268(24):6401-6407.
40 Tang KH,Li S,Jamayran AK,et al.Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC[J].Cancer Discov,2022,12(1):47-61.
41 Liu C,Lu HY,Wang HY,et al.Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling[J].Clin Cancer Res,2021,27(1):342-354.
42 Xu ZY,Guo CY,Ye QL,et al.Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization[J].Nat Commun,2021,12(1):6310.
43 Bard-Chapeau EA,Li S,Ding J,et al.Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis[J].Cancer Cell,2011,19(5):629-639.
44 Qi C,Han T,Tang H,et al.Shp2 inhibits proliferation of esophageal squamous cell cancer via dephosphorylation of stat3[J].Int J Mol Sci,2017,18(1):134.
45 Wei B,Xu LY,Guo WJ,et al.SHP2-mediated inhibition of DNA repair contributes to cGAS-STING activation and chemotherapeutic sensitivity in colon cancer[J].Cancer Res,2021,81(12):3215-3228.
46 Chen WS,Liang Y,Zong M,et al.Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment[J].Cell Rep,2021,37(6):109974.
47 Fedele C,Ran H,Diskin B,et al.SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models[J].Cancer Discov,2018,8(10):1237-1249.
48 Wong GS,Zhou J,Liu JB,et al.Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition[J].Nat Med,2018,24(7):968-977.

[1]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[2]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[3]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[4]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[5]	CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions [J]. Journal of Practical Oncology, 2022, 36(6): 520-525.
[6]	NA Ruisi, GUO Ying, SHI Jiaqi, ZHENG Tongsen. Reasons why small intestinal tunors are rare [J]. Journal of Practical Oncology, 2022, 36(6): 526-530.
[7]	WANG Xinyi, LU Yiping, SUN Zhengrong. Research progress on the effects of m6A RNA methylation modification on the biological characteristics of malignant tumors and tumor stem cells [J]. Journal of Practical Oncology, 2022, 36(6): 551-555.
[8]	ZHANG Shumin, ZHANG Gong. Research progress of ILC2s in tumor immune regulation [J]. Journal of Practical Oncology, 2022, 36(6): 566-569.
[9]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[10]	WANG Qin, LIU Junjie, LU Xiuxin, WU Yafei, ZHANG Wenhao. Research progress of nanocombination therapy based on ferroptosis in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(5): 429-434.
[11]	HUANG Yongping, LI Mengjie, SUN Yufang, XIANG Tao. Research progress of bacterial biofilms in tumor biological processes and therapeutic applications [J]. Journal of Practical Oncology, 2022, 36(5): 440-444.
[12]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[13]	SUN Weiling, ZHANG Minghui, WU Huaxing, ZHAO Yanbin. Predictive value of serum tumor markers in histopathological types of bronchoscopy biopsy in patients with lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 316-322.
[14]	SUN Fusheng, XU Ye, ZHANG Yongjian, LOU Ge. Research progress and new treatment strategies of ovarian cancer organoids [J]. Journal of Practical Oncology, 2022, 36(4): 346-350.
[15]	LI Yuan, ZHANG Ling. Research progress of mitotic catastrophe in digestive system tumors [J]. Journal of Practical Oncology, 2022, 36(4): 356-359.

The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments